- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-RNF43/ RNF124/ SSPCS monoclonal antibody
Anti-RNF43/ RNF124/ SSPCS antibody for FACS & in-vivo assay
Go to RNF43/RNF43 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T45968-Ab-1/ GM-Tg-hg-T45968-Ab-2 | Anti-Human RNF43 monoclonal antibody | Human |
| GM-Tg-rg-T45968-Ab-1/ GM-Tg-rg-T45968-Ab-2 | Anti-Rat RNF43 monoclonal antibody | Rat |
| GM-Tg-mg-T45968-Ab-1/ GM-Tg-mg-T45968-Ab-2 | Anti-Mouse RNF43 monoclonal antibody | Mouse |
| GM-Tg-cynog-T45968-Ab-1/ GM-Tg-cynog-T45968-Ab-2 | Anti-Cynomolgus/ Rhesus macaque RNF43 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T45968-Ab-1/ GM-Tg-felg-T45968-Ab-2 | Anti-Feline RNF43 monoclonal antibody | Feline |
| GM-Tg-cang-T45968-Ab-1/ GM-Tg-cang-T45968-Ab-2 | Anti-Canine RNF43 monoclonal antibody | Canine |
| GM-Tg-bovg-T45968-Ab-1/ GM-Tg-bovg-T45968-Ab-2 | Anti-Bovine RNF43 monoclonal antibody | Bovine |
| GM-Tg-equg-T45968-Ab-1/ GM-Tg-equg-T45968-Ab-2 | Anti-Equine RNF43 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T45968-Ab-1/ GM-Tg-hg-T45968-Ab-2; GM-Tg-rg-T45968-Ab-1/ GM-Tg-rg-T45968-Ab-2; GM-Tg-mg-T45968-Ab-1/ GM-Tg-mg-T45968-Ab-2; GM-Tg-cynog-T45968-Ab-1/ GM-Tg-cynog-T45968-Ab-2; GM-Tg-felg-T45968-Ab-1/ GM-Tg-felg-T45968-Ab-2; GM-Tg-cang-T45968-Ab-1/ GM-Tg-cang-T45968-Ab-2; GM-Tg-bovg-T45968-Ab-1/ GM-Tg-bovg-T45968-Ab-2; GM-Tg-equg-T45968-Ab-1/ GM-Tg-equg-T45968-Ab-2 |
| Products Name | Anti-RNF43 monoclonal antibody |
| Format | mab |
| Target Name | RNF43 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-RNF43 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species RNF43/ RNF124/ SSPCS VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMLV000103 | human RNF43 Lentivirus particle |
| ORF Viral Vector | pGMLV000103 | human RNF43 Lentivirus plasmid |
| ORF Viral Vector | vGMLV000560 | human RNF43 Lentivirus particle |
| ORF Viral Vector | pGMLV000560 | human RNF43 Lentivirus plasmid |
| ORF Viral Vector | pGMAD000385 | mouse Rnf43 Adenovirus plasmid |
| ORF Viral Vector | pGMAAV000376 | house mouse Rnf43 AAV plasmid |
| ORF Viral Vector | pGMLPm001260 | mouse Rnf43 Lentivirus plasmid |
| ORF Viral Vector | vGMAD000385 | mouse Rnf43 Adenovirus particle |
| ORF Viral Vector | vGMAAV000376 | house mouse Rnf43 AAV particle |
| ORF Viral Vector | vGMLPm001260 | mouse Rnf43 Lentivirus particle |
Target information
| Target ID | GM-T45968 |
| Target Name | RNF43 |
| Gene ID | 54894,207742,303412,710124,491114,101097109,784035,100057001 |
| Gene Symbol and Synonyms | 4732452J19Rik,RGD1305204,RNF124,RNF43,SSPCS,URCC |
| Uniprot Accession | Q68DV7 |
| Uniprot Entry Name | RNF43_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target |
| Disease | N/A |
| Gene Ensembl | ENSG00000108375 |
| Target Classification | N/A |
The target: RNF43, gene name: RNF43, also named as RNF124, SSPCS, URCC. The protein encoded by this gene is a RING-type E3 ubiquitin ligase and is predicted to contain a transmembrane domain, a protease-associated domain, an ectodomain, and a cytoplasmic RING domain. This protein is thought to negatively regulate Wnt signaling, and expression of this gene results in an increase in ubiquitination of frizzled receptors, an alteration in their subcellular distribution, resulting in reduced surface levels of these receptors. Mutations in this gene have been reported in multiple tumor cells, including colorectal and endometrial cancers. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Mar 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
